ARTICLE | Clinical News
EC approves BioCryst's Alpivab for influenza
May 4, 2018 6:58 PM UTC
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) said the European Commission approved an MAA for Alpivab peramivir to treat uncomplicated influenza in patients at least two years old.
The injectable formulation of a viral neuraminidase inhibitor is approved in multiple countries, including the U.S. and Japan. BioCryst declined to discuss its launch date or price...